Successful treatment with anakinra in generalized spiculated porokeratosis and severe hidradenitis suppurativa in a patient with MVK and MEFV mutations

Clin Exp Dermatol. 2023 Feb 2;48(2):161-165. doi: 10.1093/ced/llac023.

Authors

Ayse Oktem¹, Gunel Rasulova², Busra Cavdarli³, Seher Bostanci¹, Aylin Heper⁴, Secil Vural²

Affiliations

¹ Department of Dermatology, Faculty of Medicine, Ankara University, Ankara, Turkiye.
² Department of Dermatology, Faculty of Medicine, Koc University, İstanbul, Turkiye.
³ Department of Medical Genetics, Ankara Bilkent City Hospital, Ankara, Turkiye.
⁴ Department of Pathology, Faculty of Medicine, Ankara University, Ankara, Turkiye.

PMID: 36730507
DOI: 10.1093/ced/llac023

No abstract available

MeSH terms

Hidradenitis Suppurativa* / complications
Hidradenitis Suppurativa* / drug therapy
Humans
Interleukin 1 Receptor Antagonist Protein / genetics
Interleukin 1 Receptor Antagonist Protein / therapeutic use
Mutation
Porokeratosis* / drug therapy
Porokeratosis* / genetics
Pyrin / genetics
Skin

Substances

Interleukin 1 Receptor Antagonist Protein
MEFV protein, human
Pyrin